SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BPMC, SAGE, SOL on Behalf of Shareholders
Werte in diesem Artikel
NEW YORK, June 23, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Blueprint Medicines Corporation (NASDAQ: BPMC)'s sale to Sanofi. Under the terms of the proposed transaction, Sanofi will pay $129.00 per share in cash at closing, and Blueprint shareholders also will receive one non-tradeable contingent value right (CVR) entitling the holder to receive two potential milestone payments of $2.00 and $4.00 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808. If you are a Blueprint shareholder, click here to learn more about your legal rights and options.
Sage Therapeutics, Inc. (NASDAQ: SAGE)'s sale to Supernus Pharmaceuticals, Inc. Under the terms of the proposed transaction, Sage shareholders will receive $8.50 per share in cash, plus one non-tradable contingent value right collectively worth up to $3.50 per share in cash payable upon achieving certain net sales and commercial milestones. If you are a Sage shareholder, click here to learn more about your legal rights and options.
Emeren Group Ltd. (NYSE: SOL)'s sale to Shurya Vitra Ltd. for $0.20 in cash per ordinary share or $2.00 in cash per American Depositary Share. If you are an Emeren shareholder, click here to learn more about your legal rights and options.
Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email sadeh@halpersadeh.com or zhalper@halpersadeh.com.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
sadeh@halpersadeh.com
zhalper@halpersadeh.com
https://www.halpersadeh.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-investigation-halper-sadeh-llc-investigates-bpmc-sage-sol-on-behalf-of-shareholders-302488394.html
SOURCE Halper Sadeh LLP
Übrigens: Blueprint Medicines und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.
Ausgewählte Hebelprodukte auf Blueprint Medicines
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Blueprint Medicines
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Nachrichten zu Emeren Group Ltd (spons. ADRs)
Analysen zu Emeren Group Ltd (spons. ADRs)
Datum | Rating | Analyst | |
---|---|---|---|
02.05.2019 | Renesola Outperform | Imperial Capital | |
16.12.2015 | Renesola Buy | ROTH Capital Partners, LLC | |
03.06.2015 | Renesola Neutral | ROTH Capital Partners, LLC | |
28.11.2014 | Renesola Neutral | ROTH Capital Partners, LLC | |
26.10.2011 | Renesola neutral | Piper Jaffray & Co. |
Datum | Rating | Analyst | |
---|---|---|---|
02.05.2019 | Renesola Outperform | Imperial Capital | |
16.12.2015 | Renesola Buy | ROTH Capital Partners, LLC | |
13.07.2011 | Renesola overweight | Piper Jaffray & Co. |
Datum | Rating | Analyst | |
---|---|---|---|
03.06.2015 | Renesola Neutral | ROTH Capital Partners, LLC | |
28.11.2014 | Renesola Neutral | ROTH Capital Partners, LLC | |
26.10.2011 | Renesola neutral | Piper Jaffray & Co. | |
11.08.2011 | Renesola neutral | ROTH Capital Partners, LLC | |
10.08.2011 | Renesola neutral | Credit Suisse Group |
Datum | Rating | Analyst | |
---|---|---|---|
11.07.2011 | Renesola sell | Goldman Sachs Group Inc. |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Emeren Group Ltd (spons. ADRs) nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen